The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel human coronavirus causing the pandemic of severe pneumonia (Coronavirus Disease 2019, COVID-19). SARS-CoV-2 is highly pathogenic in human, having posed immeasurable public health challenges to the world. Innate immune response is critical for the host defense against viral infection and the dysregulation of the host innate immune responses probably aggravates SARS-CoV-2 infection, contributing to the high morbidity and lethality of COVID-19. It has been reported that some coronavirus proteins play an important role in modulating innate immunity of the host, but few studies have been conducted on SARS-CoV-2. In this study, we screened the viral proteins of SARS-CoV-2 and found that the viral ORF6, ORF8 and nucleocapsid proteins were potential inhibitors of type I interferon signaling pathway, a key component for antiviral response of host innate immune. All the three proteins showed strong inhibition on type I interferon (IFN-β) and NF-κB-responsive promoter, further examination revealed that these proteins were able to inhibit the interferon-stimulated response element (ISRE) after infection with Sendai virus, while only ORF6 and ORF8 proteins were able to inhibit the ISRE after treatment with interferon beta. These findings would be helpful for the further study of the detailed signaling pathway and unveil the key molecular player that may be targeted.

[1]  Christine A. Biron,et al.  Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente , 2006, Science.

[2]  A. Pfeifer,et al.  Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission , 2018, Scientific Reports.

[3]  Lisa E. Gralinski,et al.  MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis , 2017, mBio.

[4]  K. Lager,et al.  Coronavirus Endoribonuclease Activity in Porcine Epidemic Diarrhea Virus Suppresses Type I and Type III Interferon Responses , 2019, Journal of Virology.

[5]  Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines , 2018, Journal of Virology.

[6]  M. Fukushi,et al.  SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is further increased by a naturally occurring elongation variant , 2020, bioRxiv.

[7]  M. Catanzaro,et al.  Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 , 2020, Signal Transduction and Targeted Therapy.

[8]  Gavin J. D. Smith,et al.  Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2 , 2020, bioRxiv.

[9]  R. Sun,et al.  Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design , 2018, Science.

[10]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[11]  S. Baker,et al.  Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages , 2020, Journal of Virology.

[12]  C. Chiu,et al.  SARS-CoV-2 genomic surveillance in Taiwan revealed novel ORF8-deletion mutant and clade possibly associated with infections in Middle East , 2020, Emerging microbes & infections.

[13]  Gavin J. D. Smith,et al.  Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2 , 2020, mBio.

[14]  A. García-Sastre,et al.  The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. , 2014, Cell host & microbe.